New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia

Acute Promyelocytic Leukemia Clinical Trial

Official title:

Phase II Study of NRX 195183 Induction and NRX 195183 Combined With Arsenic Trioxide (As2o3) as Initial Consolidation Therapy Followed by Continuous NRX 195183 Maintenance Therapy for Patients With Untreated Acute Promyelocytic Leukemia

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00670150
• Other study ID #: 9L-07-12
• Status: Withdrawn
• Phase: Phase 2
• First received: April 28, 2008
• Last updated: October 24, 2015
• Start date: May 2010
• Est. completion date: August 2010

Study information

• Verified date: October 2015
• Source: University of Southern California
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The safety and efficacy of combining NRX 195183 with arsenic trioxide in treating untreated APL will be assessed.

Description:

The primary objectives of this study are in newly diagnosed APL patients:

• To evaluate the efficacy (complete and molecular response rates) and toxicity of NRX 195183 in induction therapy

• To evaluate the efficacy (molecular response rates) and toxicity of NRX 195183 in combination with arsenic trioxide (As2O3) in consolidation therapy.

• To evaluate the efficacy (event free-survival, disease-free survival) and toxicity of NRX 195183 as maintenance therapy for patients with APL who achieve a molecular complete response.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: August 2010
• Est. primary completion date: August 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis Patients must have a clinical diagnosis of acute promyelocytic leukemia (APL) morphology or FAB M3 variant confirmed by RT-PCR assay for PML-RARa or chromosome analysis/FISH showing t(15:17) translocation. A patient may be entered prior to confirmatory studies, but a patient who is subsequently found to be PML-RARa negative will be removed from protocol treatment.

• Prior Treatment The patient must not have received any systemic definitive treatment for APL, including cytotoxic chemotherapy, retinoids or arsenic trioxide. Prior therapy with corticosteroids, hydroxyurea or leukapheresis will not exclude the patient.

• Age: Patients must be of age eighteen (18) or above.

• Other Criteria

• Patients must have the following laboratory values:

• Bilirubin equal or less than 1.5 times the upper limit of normal.

• Creatinine equal or less than 1.5 times the upper limit of normal

• Pregnancy / Nursing Status

• Patients entered into this study should be non-pregnant and non-nursing and should not plan on becoming pregnant while on treatment. Treatment under this protocol would expose an unborn child to significant risks. treatment. Women and men of reproductive potential should agree to use an effective means of birth control. There is an extremely high risk of fetal malformation if pregnancy occurs while on treatment in any amount with retinoid drugs even for short periods.

Exclusion Criteria:

• Non-APL, AML patients should be excluded from the study.

• Other serious illnesses which would limit survival to 1 year.

• Psychiatric conditions which would prevent compliance with treatment or informed consent.

• Uncontrolled or severe cardiovascular disease. This would include history of a recent acute myocardial infarction, uncontrolled congestive heart failure, or active angina.

• AIDS or HIV positive patients, although HIV test is not required for accrual.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Acute Promyelocytic Leukemia
• Leukemia
• Leukemia, Promyelocytic, Acute

Intervention

Drug:
• NRX 195183 (retinoid analogue)
30mg/m2 PO daily x 3mo.in Induction, then daily with consolidation
• Arsenic Trioxide
0.15mg/kg/day over 2hrs VI on day 1-5 x 4 weeks. 2 weeks rest then repeat x 3 more cycles.

Locations

Country	Name	City	State
United States	USC/Norris Comprehensive Cancer Center	Los Angeles	California

Sponsors (2)

Lead Sponsor	Collaborator
University of Southern California	Sponsor Name Pending

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary endpoint is achieving a partial or complete response		Bone marrow biopsies will be done monthly during induction	No
Secondary	Safety and feasibility		Twice weekly during induction and then weekly during consolidation	Yes